Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EXFORGE HCT vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
EXFORGE HCT is a combination of amlodipine (a dihydropyridine calcium channel blocker), valsartan (an angiotensin II receptor blocker), and hydrochlorothiazide (a thiazide diuretic). Amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation. Valsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. Hydrochlorothiazide increases excretion of sodium and water by inhibiting the Na+/Cl- symporter in the distal convoluted tubule.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Hypertension: treatment of hypertension to lower blood pressure (FDA-approved)
Hypertension
One tablet orally once daily. Initial dose based on previous antihypertensive therapy; maximum dose is one tablet of 10 mg amlodipine/320 mg valsartan/25 mg hydrochlorothiazide per day.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Valsartan: 6 hours (terminal). Amlodipine: 30-50 hours (terminal), permits once-daily dosing. Hydrochlorothiazide: 6-15 hours (terminal).
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Amlodipine is extensively metabolized in the liver via CYP3A4; valsartan is minimally metabolized (about 20%) via CYP2C9; hydrochlorothiazide is not metabolized and is excreted unchanged.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Valsartan: 13% excreted unchanged in urine, 83% in feces via biliary secretion. Amlodipine: 10% excreted unchanged in urine, 60% as metabolites in urine, 20-25% in feces. Hydrochlorothiazide: ≥95% excreted unchanged in urine.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Valsartan: 94-97% (primarily albumin). Amlodipine: ~93% (albumin). Hydrochlorothiazide: 40-68% (albumin).
~90%, primarily to albumin
Valsartan: 17 L (0.24 L/kg); indicates limited extravascular distribution. Amlodipine: 21 L/kg; extensive tissue distribution. Hydrochlorothiazide: 3-15 L (0.05-0.2 L/kg); distributes into extracellular fluid.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: Valsartan 25% (wide range 10-35%), amlodipine 64-90%, hydrochlorothiazide 65-75%.
Oral: 50–60% (extensive first-pass metabolism)
Contraindicated in anuria. For GFR 30-60 m L/min: no dose adjustment needed, but monitor serum potassium and creatinine. For GFR <30 m L/min: not recommended due to limited data.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh Class A: no adjustment; Class B: maximum dose 5 mg amlodipine/160 mg valsartan/12.5 mg hydrochlorothiazide; Class C: not recommended.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Safety and efficacy in pediatric patients (<18 years) have not been established; no recommended dosing.
Not recommended for pediatric use; safety in children under 12 years not established.
Initiate at the lowest available dose (5 mg amlodipine/160 mg valsartan/12.5 mg hydrochlorothiazide) and titrate slowly; monitor renal function, electrolytes, and blood pressure due to increased risk of hypotension and electrolyte imbalance.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
WARNING: FETAL TOXICITY. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.
None
Fetal toxicity: avoid use in pregnancy; discontinue if pregnancy occurs.,Hypotension: symptomatic hypotension may occur, especially in volume-depleted patients.,Electrolyte and metabolic effects: hydrochlorothiazide may cause hypokalemia, hyponatremia, hypercalcemia, hypomagnesemia, and hyperglycemia.,Renal function deterioration: monitor renal function; may cause acute renal failure.,Hepatic impairment: use caution in patients with severe hepatic impairment.,Angioedema: reported with valsartan; monitor for swelling of face, lips, throat.,Avoid concomitant use with aliskiren in patients with diabetes or renal impairment.
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Hypersensitivity to any component.,Anuria (due to hydrochlorothiazide).,Concomitant use with aliskiren in patients with diabetes mellitus.,Severe renal impairment (e GFR <30 m L/min/1.73 m²).,Pregnancy (second and third trimesters).,Hereditary fructose intolerance (due to sorbitol excipient in some formulations).
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid high-potassium foods (bananas, oranges, spinach, potatoes) and salt substitutes with potassium unless instructed otherwise. Grapefruit juice may increase amlodipine levels; limit consumption. Alcohol may enhance hypotensive effects. Maintain adequate fluid intake to prevent dehydration.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
First trimester: Drugs acting on renin-angiotensin system (ARB/ACEi component: valsartan) associated with increased risk of fetal renal dysfunction, oligohydramnios, skull ossification defects, and fetal death if exposed during first trimester. However, major teratogenic risk is primarily second and third trimester. Hydrochlorothiazide (HCTZ) may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Second and third trimester: Valsartan exposure is associated with oligohydramnios, fetal renal failure, skull hypoplasia, anuria, and death. HCTZ can cause fetal electrolyte imbalances, jaundice, and thrombocytopenia. Avoid use in pregnancy, especially second and third trimesters.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Valsartan: Not known if excreted in human milk; due to potential for adverse effects on infant kidney function, caution advised. Hydrochlorothiazide: Excreted in breast milk in small amounts; M/P ratio approximately 0.6. May suppress lactation. Use only if clearly needed, monitoring infant for electrolyte disturbances and dehydration.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
Not recommended for use in pregnancy. If unavoidable, use lowest effective dose; however, pharmacokinetic changes in pregnancy (increased plasma volume, renal clearance) may require dose adjustments, but safety data insufficient. Generally, avoid use.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
Exforge HCT is a triple combination of amlodipine, valsartan, and hydrochlorothiazide. It is indicated for hypertension not adequately controlled on dual therapy. Monitor serum potassium, especially in patients with renal impairment or on NSAIDs. Avoid use in pregnancy due to direct renin-angiotensin system effects. Titrate doses based on blood pressure response. Common side effects include peripheral edema (amlodipine), dizziness, and electrolyte disturbances (HCTZ).
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take exactly as prescribed, usually once daily with or without food.,Do not stop taking this medication without consulting your doctor.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) or low blood pressure (dizziness, fainting).,Avoid potassium supplements or salt substitutes containing potassium unless advised by your doctor.,Limit alcohol intake as it may increase blood pressure or cause dizziness.,If pregnant or planning pregnancy, inform your doctor immediately as this drug can harm an unborn baby.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Stay hydrated to prevent dehydration from hydrochlorothiazide, especially if you sweat heavily or have diarrhea/vomiting.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EXFORGE HCT vs ALDORIL 15, answered by our medical review team.
EXFORGE HCT is a Antihypertensive that works by EXFORGE HCT is a combination of amlodipine (a dihydropyridine calcium channel blocker), valsartan (an angiotensin II receptor blocker), and hydrochlorothiazide (a thiazide diuretic). Amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation. Valsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. Hydrochlorothiazide increases excretion of sodium and water by inhibiting the Na+/Cl- symporter in the distal convoluted tubule.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EXFORGE HCT and ALDORIL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EXFORGE HCT is: One tablet orally once daily. Initial dose based on previous antihypertensive therapy; maximum dose is one tablet of 10 mg amlodipine/320 mg valsartan/25 mg hydrochlorothiazide per day.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EXFORGE HCT and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EXFORGE HCT is classified as Category C. First trimester: Drugs acting on renin-angiotensin system (ARB/ACEi component: valsartan) associated with increased risk of fetal renal dysfunction, oligohydramnios, skull ossifica. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.